Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Rhythm Biosciences share price lifts 5% on TGA news
Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today
Here’s why the Rhythm (ASX:RHY) share price is up 11% today
Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets
Rhythm Biosciences (ASX: RHY) share price slumps amid ‘pivotal’ board changes
Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity
These were the best performing ASX healthcare shares in October
Here’s why the Rhythm Biosciences share price (ASX:RHY) is jumping higher today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.
|13 May 2022||$1.19||$-0.01||-0.83%||202,091||$1.22||$1.23||$1.19|
|12 May 2022||$1.20||$-0.01||-0.83%||753,017||$1.29||$1.35||$1.18|
|11 May 2022||$1.21||$0.02||1.68%||238,984||$1.20||$1.23||$1.17|
|10 May 2022||$1.19||$0.01||0.85%||585,309||$1.18||$1.25||$1.12|
|09 May 2022||$1.18||$-0.10||-7.81%||493,668||$1.26||$1.26||$1.18|
|06 May 2022||$1.28||$0.03||2.40%||312,393||$1.22||$1.30||$1.20|
|05 May 2022||$1.25||$-0.04||-3.10%||293,060||$1.32||$1.32||$1.25|
|04 May 2022||$1.29||$0.01||0.78%||426,677||$1.32||$1.39||$1.28|
|03 May 2022||$1.28||$-0.08||-5.88%||163,766||$1.38||$1.38||$1.28|
|02 May 2022||$1.36||$-0.03||-2.15%||86,268||$1.37||$1.37||$1.31|
|29 Apr 2022||$1.40||$0.02||1.45%||148,857||$1.41||$1.42||$1.36|
|28 Apr 2022||$1.38||$-0.04||-2.82%||129,746||$1.43||$1.46||$1.37|
|27 Apr 2022||$1.42||$0.12||9.23%||158,166||$1.25||$1.43||$1.25|
|26 Apr 2022||$1.30||$-0.10||-7.14%||427,140||$1.38||$1.38||$1.25|
|22 Apr 2022||$1.40||$-0.02||-1.41%||208,113||$1.40||$1.44||$1.33|
|21 Apr 2022||$1.42||$0.01||0.71%||138,520||$1.42||$1.46||$1.40|
|20 Apr 2022||$1.41||$-0.05||-3.42%||274,194||$1.48||$1.50||$1.38|
|25 Nov 2021||Otto Buttula||Issued||2||$3,710,000||
Issue of options.
|25 Nov 2021||Trevor Lockett||Issued||500||$927,500||
Issue of options.
|25 Nov 2021||Louis (Lou) Panaccio||Issued||150||$278,250||
Issue of options.
|25 Nov 2021||Eduardo Vom||Issued||150||$278,250||
Issue of options.
|09 Sep 2021||Trevor Lockett||Issued||4||$4,000||
|09 Sep 2021||Trevor Lockett||Issued||4||$3,400||
|09 Sep 2021||Eduardo Vom||Issued||88||$88,818||
|09 Sep 2021||Eduardo Vom||Issued||28||$24,139||
|09 Sep 2021||Eduardo Vom||Issued||60||$51,354||
|09 Sep 2021||Louis (Lou) Panaccio||Issued||20||$17,000||
|09 Sep 2021||Louis (Lou) Panaccio||Issued||20||$20,000||
|09 Sep 2021||Otto Buttula||Issued||685||$582,251||
|09 Sep 2021||Otto Buttula||Issued||685||$685,002||
|Mr Otto Leslie Steven Buttula||Executive ChairmanExecutive Director||Oct 2019||
Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited. Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit and Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
|Mr Louis (Lou) James Panaccio||Non-Executive Director||Aug 2017||
Mr Panaccio has experience in business and healthcare services. Lou is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Therapeutics, Inc. Lou is also on the board of Unison Housing Limited. He has more than twenty years of experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
|Dr Trevor John Lockett||Executive DirectorTechnical Director||Jun 2017||
Mr Lockett has over 30 years of research experience, at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT
|Mr Glenn Gilbert||Chief Executive OfficerManaging Director||Dec 2021||
|Mr Eduardo Vom||Non-Executive Director||Jun 2020||
Mr Vom has over 20 years of experience in technology and development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He currently serves as a non-executive director with privately owned health and wellbeing companies and has experience in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation.
|Dr Rachel David||Non-Executive Director||Dec 2021||
Dr David is an experienced senior health and financial services sector executive with understanding of the complex interplay between government, business, media and the community. Her career has spanned over 25 years in healthcare, particularly relating to evidence-based practice and access to new technologies. She is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). This includes the two major listed companies, Medibank and nib. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.
|Ms Andrea Steele||Company SecretaryGeneral Counsel||Feb 2022||
|Andrea Steele||Company SecretaryGeneral Counsel||
|Webinvest Pty Ltd||16,666,667||8.24%|
|Newfound Investments Pty Ltd||10,733,333||5.31%|
|Ferndale Securities Pty Ltd||10,100,000||4.99%|
|Loumea Investment Pty Ltd||9,915,000||4.90%|
|Northern Star Nominees Pty Ltd||7,200,000||3.56%|
|Mrs Sarah Cameron||6,300,000||3.12%|
|Rojo Nero Capital Pty Ltd||4,166,668||2.06%|
|Giokir Pty Ltd||3,400,000||1.68%|
|Mr Hsien Michael Soo||3,224,783||1.59%|
|Jawaf Enterprises Pty Ltd||3,150,000||1.56%|
|Commonwealth Scientific & Industrial Research Organisation||2,500,000||1.24%|
|Mr Daniel Eddington & Mrs Julie Eddington||2,460,000||1.22%|
|Ms Natalie Louise Patterson||2,416,666||1.19%|
|Garnsworthy Pension Fund Pty Ltd||2,250,000||1.11%|
|Dr Gavin James Shepherd & Mrs Catherine Shepherd||2,000,000||0.99%|
|E & W Nominee Pty Ltd||2,000,000||0.99%|
|Dc & Pc Holdings Pty Ltd||1,750,000||0.87%|
|Mr Richard Stanley De Ravin||1,600,000||0.79%|
|Dr Paul Maxwell Miller & Mrs Louise Monique Miller||1,509,188||0.75%|
|HSBC Custody Nominees (Australia) Limited||1,491,945||0.74%|